Sanofi shelves mRNA seasonal flu effort, pivots to proven vaccines

Sanofi has deprioritized its phase 1 mRNA seasonal flu program, scrapping the effort as part of a broader strategic shift, while continuing to pursue an mRNA vaccine for an H5 pandemic and focusing on established influenza vaccines (Fluzone High-Dose, Flublok). The influenza/COVID vaccine franchise generated €2.3 billion last year, a 6% decline from 2024 amid lower US immunization rates, and the company underscored a multi‑platform vaccine strategy, including the Dynavax acquisition, as its growth path.